Peptron, Inc.

KOSDAQ 087010.KQ

Peptron, Inc. Return on Assets (ROA) for the year ending December 31, 2023: -30.33%

Peptron, Inc. Return on Assets (ROA) is -30.33% for the year ending December 31, 2023, a -37.47% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • Peptron, Inc. Return on Assets (ROA) for the year ending December 31, 2022 was -22.06%, a -14.21% change year over year.
  • Peptron, Inc. Return on Assets (ROA) for the year ending December 31, 2021 was -19.32%, a -23.69% change year over year.
  • Peptron, Inc. Return on Assets (ROA) for the year ending December 31, 2020 was -15.62%, a 46.24% change year over year.
  • Peptron, Inc. Return on Assets (ROA) for the year ending December 31, 2019 was -29.05%, a -459.52% change year over year.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
KOSDAQ: 087010.KQ

Peptron, Inc.

CEO Mr. Ho-Il Choi
IPO Date July 22, 2015
Location South Korea
Headquarters 37-24, Yuseong-daero 1628 beon-gil
Employees 94
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email